Skip to main content

Allergan oral migraine drug succeeds in study

June 11 (Reuters) - Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.